BioPharma Resources

Drug Trial Radar · NCT05896254

Study of MAR001 in Adults With Metabolic Dysfunction

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction

Last checked: Nov 19, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Jul 22, 2023

Primary completion

Dec 13, 2024

Study completion Dec 13, 2024

Sponsor

Lead sponsor
Marea TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.

Conditions

  • Hypertriglyceridemia

Interventions

  • MAR001Drug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of MAR001Time frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brisbane Site

    Brisbane, Australia

  • Melbourne Site

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.